Walter Masson, Martín Lobo, Juan P Nogueira, Pablo Corral, Leandro Barbagelata, Daniel Siniawski
{"title":"Inhibitors of apolipoprotein C3, triglyceride levels, and risk of pancreatitis: a systematic review and meta-analysis.","authors":"Walter Masson, Martín Lobo, Juan P Nogueira, Pablo Corral, Leandro Barbagelata, Daniel Siniawski","doi":"10.1007/s11154-024-09893-x","DOIUrl":null,"url":null,"abstract":"<p><p>In recent years, novel apoC3 inhibitor therapies for the treatment of hypertriglyceridemia have been developed and assessed through phase II and III clinical trials. The objective of this study was to perform an updated meta-analysis on the impact of new apoC3 inhibitor drugs on triglyceride and apoC3 levels, as well as on the incidence of pancreatitis. We conducted a meta-analysis of randomized, placebo-controlled studies assessing the effects of apoC3 inhibitors therapy (antisense oligonucleotides and small interfering RNA) on triglyceride levels, apoC3 levels, and the occurrence of acute pancreatitis. This meta-analysis was performed according to PRISMA guidelines. The random-effects model was performed. Nine randomized clinical trials (n = 717 patients) were considered eligible for this systematic review. ApoC3 inhibitor drugs were consistently associated with decreased triglyceride levels (MD -57.0%; 95% CI -61.9 to -52.1, I<sup>2</sup> 82%) and lowered apoC3 values (MD -76; 95% CI -80.1 to -71.8, I<sup>2</sup> 77%) when compared to placebo. Furthermore, the use of apoC3 inhibitor drugs demonstrated a reduction in the risk of acute pancreatitis (OR 0.11; 95% CI 0.04 to 0.27, I<sup>2</sup> 0%). The present updated meta-analysis of randomized clinical trials demonstrated that the utilization of apoC3 inhibitors in patients with hypertriglyceridemia correlated with reduced apoC3 and triglyceride levels, along with a decreased risk of acute pancreatitis compared to the placebo.</p>","PeriodicalId":21106,"journal":{"name":"Reviews in Endocrine & Metabolic Disorders","volume":null,"pages":null},"PeriodicalIF":6.9000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Reviews in Endocrine & Metabolic Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1007/s11154-024-09893-x","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/7/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0
Abstract
In recent years, novel apoC3 inhibitor therapies for the treatment of hypertriglyceridemia have been developed and assessed through phase II and III clinical trials. The objective of this study was to perform an updated meta-analysis on the impact of new apoC3 inhibitor drugs on triglyceride and apoC3 levels, as well as on the incidence of pancreatitis. We conducted a meta-analysis of randomized, placebo-controlled studies assessing the effects of apoC3 inhibitors therapy (antisense oligonucleotides and small interfering RNA) on triglyceride levels, apoC3 levels, and the occurrence of acute pancreatitis. This meta-analysis was performed according to PRISMA guidelines. The random-effects model was performed. Nine randomized clinical trials (n = 717 patients) were considered eligible for this systematic review. ApoC3 inhibitor drugs were consistently associated with decreased triglyceride levels (MD -57.0%; 95% CI -61.9 to -52.1, I2 82%) and lowered apoC3 values (MD -76; 95% CI -80.1 to -71.8, I2 77%) when compared to placebo. Furthermore, the use of apoC3 inhibitor drugs demonstrated a reduction in the risk of acute pancreatitis (OR 0.11; 95% CI 0.04 to 0.27, I2 0%). The present updated meta-analysis of randomized clinical trials demonstrated that the utilization of apoC3 inhibitors in patients with hypertriglyceridemia correlated with reduced apoC3 and triglyceride levels, along with a decreased risk of acute pancreatitis compared to the placebo.
近年来,用于治疗高甘油三酯血症的新型载脂蛋白C3抑制剂疗法不断开发出来,并通过II期和III期临床试验进行了评估。本研究旨在对新型载脂蛋白C3抑制剂药物对甘油三酯和载脂蛋白C3水平以及胰腺炎发病率的影响进行最新的荟萃分析。我们对随机安慰剂对照研究进行了荟萃分析,评估了载脂蛋白C3抑制剂疗法(反义寡核苷酸和小干扰RNA)对甘油三酯水平、载脂蛋白C3水平和急性胰腺炎发生率的影响。这项荟萃分析是根据PRISMA指南进行的。采用随机效应模型。九项随机临床试验(n = 717 例患者)被认为符合本系统综述的条件。与安慰剂相比,载脂蛋白C3抑制剂药物始终与甘油三酯水平下降(MD -57.0%; 95% CI -61.9 to -52.1,I2 82%)和载脂蛋白C3值降低(MD -76; 95% CI -80.1 to -71.8,I2 77%)相关。此外,使用载脂蛋白C3抑制剂可降低急性胰腺炎的风险(OR 0.11;95% CI 0.04 至 0.27,I2 0%)。本随机临床试验的最新荟萃分析表明,与安慰剂相比,高甘油三酯血症患者使用载脂蛋白C3抑制剂可降低载脂蛋白C3和甘油三酯水平,同时降低急性胰腺炎的风险。
期刊介绍:
Reviews in Endocrine and Metabolic Disorders is an international journal dedicated to the field of endocrinology and metabolism. It aims to provide the latest advancements in this rapidly advancing field to students, clinicians, and researchers. Unlike other journals, each quarterly issue of this review journal focuses on a specific topic and features ten to twelve articles written by world leaders in the field. These articles provide brief overviews of the latest developments, offering insights into both the basic aspects of the disease and its clinical implications. This format allows individuals in all areas of the field, including students, academic clinicians, and practicing clinicians, to understand the disease process and apply their knowledge to their specific areas of interest. The journal also includes selected readings and other essential references to encourage further in-depth exploration of specific topics.